Alnylam Pharma (ALNY) Tops Q4 EPS by 19c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $321.59 --0%
Revenue Growth %: +70.6%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
CRMT, PKE, HELE, More
Revenue Growth %: +70.6%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($2.09), $0.19 better than the analyst estimate of ($2.28). Revenue for the quarter came in at $21.03 million versus the consensus estimate of $15.12 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
- JPMorgan Starts J&T Global Express (1519:HK) at Overweight
- HSBC Reiterates Buy Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
